Baidu
map

感染

订阅

MedSci主页 / 所有栏目 / 感染

Neurology：脑出血后谷氨酰胺水平降低导致感染风险增加

2018-07-01 zhangfan MedSci原创

谷氨酰胺动脉瘤性蛛网膜下腔出血医院获得性感染
关注

研究认为动脉瘤性蛛网膜下腔出血后谷氨酰胺水平降低导致医院获得性感染风险增加

近日研究人员就动脉瘤性蛛网膜下腔出血(SAH)后血清谷氨酰胺水平变化及其与医院获得性感染(HAIS)之间的关系进行了考察。

SAH患者在出血后14天内测定每日热量摄入量和C反应蛋白、转胸腺肽、肿瘤坏死因子受体1a(TNFαr1a)、谷氨酰胺和氮平衡水平。通过多变量模型考察血清谷氨酰胺水平与 HAI之间的关系，每日追踪HAIS并进行时间-事件分析，SAH后3个月评估患者认知和Rankin得分。

77名患者参与研究，平均年龄55岁，SAH后8 ± 3天，发生18例(23%)HAI。多因素线性评估显示，负氮平衡以及TNFαR1a升高导致血清谷氨酰胺水平增加。14天血清谷氨酰胺水平降低人群(166 ± 110 vs 236 ± 81 μg/mL， p = 0.004)HAI风险增加。入院Hunt-Hess评分以及血清谷氨酰胺水平低增加HAI风险。14天平均血清谷氨酰胺水平较低与认知得分下降以及3个月Rankin评估差相关。

研究认为动脉瘤性蛛网膜下腔出血后谷氨酰胺水平降低导致医院获得性感染风险增加。

原始出处：


本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2000483, encodeId=316420004834c, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Jul 07 05:31:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328449, encodeId=82c6328449eb, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Sun Jul 01 12:35:27 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328448, encodeId=e0e43284484a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Jul 01 11:57:18 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328438, encodeId=ed55328438d2, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Sun Jul 01 11:38:03 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328418, encodeId=7997328418cb, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Sun Jul 01 09:51:32 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328406, encodeId=6e333284066c, content=学习了.学习了.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun Jul 01 09:32:19 CST 2018, time=2018-07-01, status=1, ipAttribution=)]
    2018-07-07 yinhl1978

    #Neurol#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2000483, encodeId=316420004834c, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Jul 07 05:31:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328449, encodeId=82c6328449eb, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Sun Jul 01 12:35:27 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328448, encodeId=e0e43284484a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Jul 01 11:57:18 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328438, encodeId=ed55328438d2, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Sun Jul 01 11:38:03 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328418, encodeId=7997328418cb, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Sun Jul 01 09:51:32 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328406, encodeId=6e333284066c, content=学习了.学习了.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun Jul 01 09:32:19 CST 2018, time=2018-07-01, status=1, ipAttribution=)]
    2018-07-01 张新亮1853311252142e2fm

    好文献学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2000483, encodeId=316420004834c, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Jul 07 05:31:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328449, encodeId=82c6328449eb, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Sun Jul 01 12:35:27 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328448, encodeId=e0e43284484a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Jul 01 11:57:18 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328438, encodeId=ed55328438d2, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Sun Jul 01 11:38:03 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328418, encodeId=7997328418cb, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Sun Jul 01 09:51:32 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328406, encodeId=6e333284066c, content=学习了.学习了.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun Jul 01 09:32:19 CST 2018, time=2018-07-01, status=1, ipAttribution=)]
    2018-07-01 医者仁心5538

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2000483, encodeId=316420004834c, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Jul 07 05:31:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328449, encodeId=82c6328449eb, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Sun Jul 01 12:35:27 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328448, encodeId=e0e43284484a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Jul 01 11:57:18 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328438, encodeId=ed55328438d2, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Sun Jul 01 11:38:03 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328418, encodeId=7997328418cb, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Sun Jul 01 09:51:32 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328406, encodeId=6e333284066c, content=学习了.学习了.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun Jul 01 09:32:19 CST 2018, time=2018-07-01, status=1, ipAttribution=)]
    2018-07-01 龙胆草

    学习谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2000483, encodeId=316420004834c, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Jul 07 05:31:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328449, encodeId=82c6328449eb, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Sun Jul 01 12:35:27 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328448, encodeId=e0e43284484a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Jul 01 11:57:18 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328438, encodeId=ed55328438d2, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Sun Jul 01 11:38:03 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328418, encodeId=7997328418cb, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Sun Jul 01 09:51:32 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328406, encodeId=6e333284066c, content=学习了.学习了.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun Jul 01 09:32:19 CST 2018, time=2018-07-01, status=1, ipAttribution=)]
    2018-07-01 131****1460

    学习了受益匪浅

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2000483, encodeId=316420004834c, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Jul 07 05:31:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328449, encodeId=82c6328449eb, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Sun Jul 01 12:35:27 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328448, encodeId=e0e43284484a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Jul 01 11:57:18 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328438, encodeId=ed55328438d2, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Sun Jul 01 11:38:03 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328418, encodeId=7997328418cb, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Sun Jul 01 09:51:32 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328406, encodeId=6e333284066c, content=学习了.学习了.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun Jul 01 09:32:19 CST 2018, time=2018-07-01, status=1, ipAttribution=)]
    2018-07-01 虈亣靌

    学习了.学习了.学习了

    0

相关资讯

危重患者应用谷氨酰胺，看看全新专家意见怎么说？

谷氨酰胺（GLN）作为人体氨基酸之一，广泛地参与机体的各种生物活动。在危重症状况下，适宜的GLN 供给对于维持正常肠屏障功能、降低炎性介质水平是必需的。中国营养学会临床营养分会组织相关专家制定了《谷氨酰胺在危重症患者中临床应用的专家推荐意见》。主要推荐意见谷氨酰胺在重症烧伤患者中的应用●GLN适用于烧伤面积在20%～70%的患者，如有吸入性损伤、多发伤和电击伤等特殊原因烧伤的患者，即便烧伤面积小于

Sci Rep：前列腺癌中，谷氨酰胺利用率代谢差异能够导致代谢缺陷

新肿瘤精准医疗范例关注于鉴定代谢的、蛋白组学的、转录组学的和基因组学在肿瘤中的变化，以期能从这些变化中来调整治疗方案和改善病人治疗结果。代谢的变化是癌症的一种标志，并且代谢通路的抑制是目前靶向治疗癌症化学疗法的一种主要策略。然而，用来对代谢亚型分类的非侵入性生物标记还存在不足现象。最近，有研究人员进行旨在鉴定4中前列腺癌细胞系且具有不同程度恶化的细胞内和细胞外代谢情况的研究。研究人员调查了恶性前列

EMBO J：切断谷氨酰胺来源，给癌细胞致命一击！

大多数癌症需要大量的谷氨酰胺用于快速生长，并且有许多研究表明，如果没有它，癌细胞就不能存活，这种现象称为“谷氨酰胺成瘾”。这可能使得阻止肿瘤的谷氨酰胺摄取成为潜在的治疗策略。来自德国柏林和维尔茨堡的研究人员的一项研究得出结论，虽然谷氨酰胺的剥夺将阻止某些肿瘤细胞的增殖，但大多数肿瘤细胞不会被杀死，从而引发了这样的治疗性干预是否会导致癌症缓解的问题。该研究近日在“EMBO杂志”上发表。

JCI:补充谷氨酰胺可以抑制单纯疱疹病毒重新激活

谷氨酰胺可增强IFN-γ相关的免疫应答并降低潜伏单纯性疱疹病毒感染的再活化速率。

Diabetes：谷氨酰胺诱导胰高血糖素样肽1（GLP-1）的分泌受活化的谷氨酸脱氢酶调控。

胰高血糖素样肽-1（GLP-1），由肠L细胞分泌，血糖依赖性地刺激β细胞分泌胰岛素。血糖依赖性这一特点可预防低血糖，使GLP-1类似物可作为2型糖尿病的一种安全有效的治疗方式。Lotta E.Andersson等人以分泌胰岛素的细胞系（INS-1 832/13）作参考，在L细胞系（GLUTag）和小鼠活体内研究GLP-1分泌是如何代谢偶联。DMG，是一种可渗透的谷氨酰胺类似物（二甲基谷氨酰胺），是

谷氨酰胺在危重症患者中临床应用的专家推荐意见（节录）

简要介绍：谷氨酰胺（glutamine，GLN）作为人体氨基酸之一，广泛地参与机体的各种生物活动。正常生理状况下，机体肌肉组织中的谷氨酰胺合成酶自身合成GLN。但当机体处于全身炎性反应、创伤及大手术等危重状态时，GLN 参与多种应激反应过程，而自身合成的GLN 却无法满足机体所需，须额外补充，因此GLN 是一种重要的条件必需氨基酸。研究表明，在危重症状况下，适宜的GLN 供给对于维持正常肠屏障功能

Baidu
map
Baidu
map
Baidu
map